Acalabrutinib Plus Rituximab “Highly Effective” in Older MCL Patients
Acalabrutinib and rituximab can yield early complete responses in older patients with previously untreated mantle cell lymphoma.
Diagnosis & Disease Information
Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma Subtypes
Research presented at the 2023 Tandem Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR demonstrated favorable results for various types of lymphoma.
Mantle Cell Lymphoma Younger Trial Shows Survival Improvement in Long-Term Follow Up Study
Researchers sought to evaluate first-line treatment of patients with advanced-stage MCL who were younger than 66 years of age.
Elderly Patients With Mantle Cell Lymphoma May Benefit From Rituximab Maintenance
Researchers sought to determine whether rituximab maintenance therapy would have a clinical benefit in elderly patients with mantle cell lymphoma.
Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Bendamustine Plus Rituximab Appears Effective in Treating First-Line, Transplant-Eligible Mantle Cell Lymphoma
Researchers sought to determine whether first-line rituximab plus bendamustine followed by ASCT would be an effective treatment option for MCL.
Real-World Treatment Outcomes, Roles of Transplantation and Maintenance Rituximab in Mantle Cell Lymphoma
Researchers sought to determine the role and utilization of ASCT in younger patients with MCL.
Mantle Cell Lymphoma: Long-Extending Remissions With Lenalidomide, Rituximab
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
- Loading...
Loading...
Next post in ASH 2020
Loading... 
Loading...